These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24213148)

  • 41. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
    Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
    Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
    Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
    Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers ME; Maris MB; Laport GG; Chauncey TR; Lange T; Langston AA; Storer B; Georges GE
    Haematologica; 2011 Aug; 96(8):1113-20. PubMed ID: 21508120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.
    Gibson JF; Alpdogan O; Subtil A; Girardi M; Wilson LD; Roberts K; Foss F
    J Am Acad Dermatol; 2015 Jun; 72(6):1010-5.e5. PubMed ID: 25981001
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
    Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
    Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Haen SP; Groh C; Schumm M; Backert L; Löffler MW; Federmann B; Faul C; Dörfel D; Vogel W; Handgretinger R; Kanz L; Bethge WA
    Ann Hematol; 2017 May; 96(5):817-827. PubMed ID: 28247058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil.
    Oka T; Sugaya M; Cury-Martins J; Vasconcelos-Berg R; Suga H; Miyagaki T; Scheinberg P; Fujita H; Izutsu K; Sato S; Sanches JA
    J Dermatol; 2016 Jun; 43(6):638-42. PubMed ID: 26602996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
    Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
    Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review.
    Johnson WT; Mukherji R; Kartan S; Nikbakht N; Porcu P; Alpdogan O
    Chin Clin Oncol; 2019 Feb; 8(1):12. PubMed ID: 30525754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
    Weng WK; Arai S; Rezvani A; Johnston L; Lowsky R; Miklos D; Shizuru J; Muffly L; Meyer E; Negrin RS; Wang E; Almazan T; Million L; Khodadoust M; Li S; Hoppe RT; Kim YH
    Blood Adv; 2020 Sep; 4(18):4474-4482. PubMed ID: 32941647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
    Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
    Nagler A; Or R; Naparstek E; Varadi G; Slavin S
    Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overview of Cutaneous T-Cell Lymphomas.
    Larocca CA; LeBoeuf NR
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):669-686. PubMed ID: 31229162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis.
    Iqbal M; Reljic T; Ayala E; Sher T; Murthy H; Roy V; Foran J; Tun H; Kumar A; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):76-82. PubMed ID: 31494227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.